Asked by: William Wragg (Independent - Hazel Grove)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the public purse of children admitted to A&E for accidents aged (a) 0 up to 4 years, (b) 4 up to 11 years and (c) 11 to 16 years of age in each of the last five years.
Answered by Steve Barclay - Secretary of State for Environment, Food and Rural Affairs
The requested information is not centrally held.
Asked by: William Wragg (Independent - Hazel Grove)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost of NHS mental health treatment for children aged (a) 0 up to 4 years, (b) 4 up to 11 years and (c) 11 to 16 years in each of the last five years.
Answered by Jackie Doyle-Price
This information is not collected in the format requested.
The Five Year Forward View Dashboard tracks expenditure for mental health at a national, regional and clinical commissioning group level and is available at:
https://www.england.nhs.uk/publication/mental-health-five-year-forward-view-dashboard
Asked by: William Wragg (Independent - Hazel Grove)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he makes of the cost effectiveness of smoking cessation products dispensed via the NHS in ensuring that patients quit cigarettes for longer than four weeks; and if he will make a statement.
Answered by Steve Brine
No separate assessment has been made of the effectiveness of smoking cessation products dispensed via the National Health Service in ensuring that patients quit cigarettes for longer than four weeks. There is evidence that smoking cessation products are effective in supporting smokers to quit, in particular when combined with specialist support. In the latter case smokers are four times as likely to stop smoking successfully as those who attempt to quit unaided or with over the counter nicotine replacement therapy.
Asked by: William Wragg (Independent - Hazel Grove)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate he has made of the number and proportion of people in recipient of smoking cessation products dispensed via the NHS who have subsequently quit cigarettes for longer than four weeks in each of the last three years.
Answered by Steve Brine
NHS Digital collects and publishes information delivered by local stop smoking services which are commissioned by local authorities. This includes information on the number of quit attempts by the type of pharmacotherapy received and whether the quit attempt was successful or not.
This a count of quit attempts and not people so those attempting to quit more than once in the time period will have each attempt recorded.
This information can be found in the attached document, with data collated from the NHS Digital publications, for years 2016-17, 2015-16 and 2014-15 available at the following links:
Asked by: William Wragg (Independent - Hazel Grove)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much his Department has spent on dispensing smoking cessation products via the NHS in each of the last three years.
Answered by Steve Brine
Information is only available centrally on the cost of smoking cessation medication that has been dispensed to National Health Service patients using the FP10 prescription form. There are various other routes in which such medication can be supplied to a patient from the NHS including from community pharmacies via voucher schemes and a direct supply to patients from a Patient Group Direction.
Smoking cessation drugs are classified under section British National Formulary (BNF) 4.10.2, Nicotine dependence, using the BNF classification system prior to edition 70.
The following table provides the Net Ingredient Cost (NIC) of smoking cessation medication where they have only been dispensed in the community via an FP10 form in England in the specified years.
Year | NIC (£) |
2015 | 34,692,508 |
2016 | 29,263,595 |
2017 | 27,353,738 |
Source: Prescription Cost Analysis NHS Digital
Notes:
1. Prescription Cost Analysis (PCA) Data
Prescription information is taken from the PCA system, supplied by NHS Prescription Services, a division of NHS Business Services Authority, and is based on a full analysis of all prescriptions dispensed in the community i.e. by community pharmacists and appliance contractors, dispensing doctors, and prescriptions submitted by prescribing doctors for items personally administered in England. Also included are prescriptions written in Wales, Scotland, Northern Ireland and the Isle of Man but dispensed in England. The data do not cover drugs dispensed in hospitals, including mental health trusts, or private prescriptions. (Prescribers are general practitioners, hospital doctors, dentists and non-medical prescribers such as nurses and pharmacists.)
2. Net Ingredient Cost (NIC)
This is the basic cost of a drug as used in primary care. This is the cost at list price excluding VAT, i.e. the price listed in the national Drug Tariff or in standard price lists and is not necessarily the price the NHS paid. It does not take into account any contract prices or discounts, dispensing costs, fees or prescription charge income, so the amount the NHS paid will be different. NIC is used in Prescription Services reports and other analyses, as it standardises cost throughout prescribing nationally, and allows comparisons of data from different sources. The figures are in pounds.
3. BNF Classifications
The PCA system uses the therapeutic classifications defined in the BNF using the classification system prior to edition 70. Information on why a drug is prescribed is not available in this dataset. Since drugs can be prescribed to treat more than one condition, it may not be possible to separate the different conditions for which a drug may have been prescribed.
The primary purpose of the BNF is to provide information for clinicians. The format of the BNF was changed with Edition 70 (September 2015 - March 2016) to make it more user friendly. However the NHS Business Service Authority, who process dispensed prescription forms and collects dispensed prescribing data and produce the PCA data, continue to use the old BNF classification system to code medicines, which has become widely used in the United Kingdom as a classification to allow comparisons between drug groups. For example it is used to report cost and trend in medicines use and supports several NHS Digital official publications. The data are used in many NHS IT systems.
Asked by: William Wragg (Independent - Hazel Grove)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, with reference to Public Health England's announcement of 20 June 2017 on the HIV PrEP Impact trial in England, how long he expects genitourinary medicine clinics and trial sites to take to prepare in readiness for the trial once the drug procurement contract for the trial has been agreed.
Answered by Steve Brine
The HIV pre-exposure prophylaxis (PrEP) Impact trial will seek to engage as many of the approximately 230 genitourinary medicine clinics in England as possible. All clinics will be offered the opportunity to participate, regardless of where they are situated. In keeping with the open access nature of sexual health services, patients will be able to attend any clinic in England that is participating in the trial and therefore have their trial eligibility assessed regardless of where they live.
NHS England and Public Health England have stated that the trial will begin by the summer of 2017, available to view here:
https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england
The final timescale will be considered at the July meeting of the PrEP Programme Oversight Board (POB) when updated information on the likely timeline of availability of trial drug at trial sites will be provided. Several bids to supply the trial drug were received on the June 29 deadline. If the trial timeline needs to change, new information will be provided in the Stakeholder Update due to be issued after the July 14 PrEP POB.
The Frequently Asked Questions will be published following review at the July meeting of the PrEP POB.
The PrEP Impact trial application was submitted to the Research Ethics Committee (REC) at the end of June. The committee will issue a final ethical opinion within 60 days. The current expectation is that approval will be obtained in time for the drug becoming available. The REC approval timeline is independent of the trial drug procurement process.
Before a trial site can begin to recruit patients, they must provide confirmation of capacity and capability to the Trial co-ordination centre and the timescales for this can vary across localities. This process includes negotiating and finalising local trial contracts and having site staff undergo trial-specific training provided by the Trial co-ordination centre (St Stephen’s Clinical Research). This process will occur in parallel to obtaining national ethics approval and the trial drug procurement activities. Some sites may be in a position to begin trial participant recruitment as soon as the trial drug becomes available.
Asked by: William Wragg (Independent - Hazel Grove)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, with reference to Public Health England's announcement of 20 June 2017 on the HIV PrEP Impact trial in England, how long he expects it will take to receive approval from the Research Ethics Committee once the drug procurement contract for the trial has been agreed.
Answered by Steve Brine
The HIV pre-exposure prophylaxis (PrEP) Impact trial will seek to engage as many of the approximately 230 genitourinary medicine clinics in England as possible. All clinics will be offered the opportunity to participate, regardless of where they are situated. In keeping with the open access nature of sexual health services, patients will be able to attend any clinic in England that is participating in the trial and therefore have their trial eligibility assessed regardless of where they live.
NHS England and Public Health England have stated that the trial will begin by the summer of 2017, available to view here:
https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england
The final timescale will be considered at the July meeting of the PrEP Programme Oversight Board (POB) when updated information on the likely timeline of availability of trial drug at trial sites will be provided. Several bids to supply the trial drug were received on the June 29 deadline. If the trial timeline needs to change, new information will be provided in the Stakeholder Update due to be issued after the July 14 PrEP POB.
The Frequently Asked Questions will be published following review at the July meeting of the PrEP POB.
The PrEP Impact trial application was submitted to the Research Ethics Committee (REC) at the end of June. The committee will issue a final ethical opinion within 60 days. The current expectation is that approval will be obtained in time for the drug becoming available. The REC approval timeline is independent of the trial drug procurement process.
Before a trial site can begin to recruit patients, they must provide confirmation of capacity and capability to the Trial co-ordination centre and the timescales for this can vary across localities. This process includes negotiating and finalising local trial contracts and having site staff undergo trial-specific training provided by the Trial co-ordination centre (St Stephen’s Clinical Research). This process will occur in parallel to obtaining national ethics approval and the trial drug procurement activities. Some sites may be in a position to begin trial participant recruitment as soon as the trial drug becomes available.
Asked by: William Wragg (Independent - Hazel Grove)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, with reference to Public Health England's announcement of 20 June 2017 on the HIV PrEP Impact trial in England, when the frequently asked questions document referred to in the announcement will be published.
Answered by Steve Brine
The HIV pre-exposure prophylaxis (PrEP) Impact trial will seek to engage as many of the approximately 230 genitourinary medicine clinics in England as possible. All clinics will be offered the opportunity to participate, regardless of where they are situated. In keeping with the open access nature of sexual health services, patients will be able to attend any clinic in England that is participating in the trial and therefore have their trial eligibility assessed regardless of where they live.
NHS England and Public Health England have stated that the trial will begin by the summer of 2017, available to view here:
https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england
The final timescale will be considered at the July meeting of the PrEP Programme Oversight Board (POB) when updated information on the likely timeline of availability of trial drug at trial sites will be provided. Several bids to supply the trial drug were received on the June 29 deadline. If the trial timeline needs to change, new information will be provided in the Stakeholder Update due to be issued after the July 14 PrEP POB.
The Frequently Asked Questions will be published following review at the July meeting of the PrEP POB.
The PrEP Impact trial application was submitted to the Research Ethics Committee (REC) at the end of June. The committee will issue a final ethical opinion within 60 days. The current expectation is that approval will be obtained in time for the drug becoming available. The REC approval timeline is independent of the trial drug procurement process.
Before a trial site can begin to recruit patients, they must provide confirmation of capacity and capability to the Trial co-ordination centre and the timescales for this can vary across localities. This process includes negotiating and finalising local trial contracts and having site staff undergo trial-specific training provided by the Trial co-ordination centre (St Stephen’s Clinical Research). This process will occur in parallel to obtaining national ethics approval and the trial drug procurement activities. Some sites may be in a position to begin trial participant recruitment as soon as the trial drug becomes available.
Asked by: William Wragg (Independent - Hazel Grove)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, with reference to Public Health England's announcement of 20 June 2017 on the HIV PrEP Impact trial in England, when the timeline for the next steps of the trial referred to in the announcement will be published.
Answered by Steve Brine
The HIV pre-exposure prophylaxis (PrEP) Impact trial will seek to engage as many of the approximately 230 genitourinary medicine clinics in England as possible. All clinics will be offered the opportunity to participate, regardless of where they are situated. In keeping with the open access nature of sexual health services, patients will be able to attend any clinic in England that is participating in the trial and therefore have their trial eligibility assessed regardless of where they live.
NHS England and Public Health England have stated that the trial will begin by the summer of 2017, available to view here:
https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england
The final timescale will be considered at the July meeting of the PrEP Programme Oversight Board (POB) when updated information on the likely timeline of availability of trial drug at trial sites will be provided. Several bids to supply the trial drug were received on the June 29 deadline. If the trial timeline needs to change, new information will be provided in the Stakeholder Update due to be issued after the July 14 PrEP POB.
The Frequently Asked Questions will be published following review at the July meeting of the PrEP POB.
The PrEP Impact trial application was submitted to the Research Ethics Committee (REC) at the end of June. The committee will issue a final ethical opinion within 60 days. The current expectation is that approval will be obtained in time for the drug becoming available. The REC approval timeline is independent of the trial drug procurement process.
Before a trial site can begin to recruit patients, they must provide confirmation of capacity and capability to the Trial co-ordination centre and the timescales for this can vary across localities. This process includes negotiating and finalising local trial contracts and having site staff undergo trial-specific training provided by the Trial co-ordination centre (St Stephen’s Clinical Research). This process will occur in parallel to obtaining national ethics approval and the trial drug procurement activities. Some sites may be in a position to begin trial participant recruitment as soon as the trial drug becomes available.
Asked by: William Wragg (Independent - Hazel Grove)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, with reference to Public Health England's announcement of 20 June 2017 on the HIV PrEP Impact trial in England, what steps are being taken to ensure that high-risk patients are able to access the trial outside London, Manchester and Brighton.
Answered by Steve Brine
The HIV pre-exposure prophylaxis (PrEP) Impact trial will seek to engage as many of the approximately 230 genitourinary medicine clinics in England as possible. All clinics will be offered the opportunity to participate, regardless of where they are situated. In keeping with the open access nature of sexual health services, patients will be able to attend any clinic in England that is participating in the trial and therefore have their trial eligibility assessed regardless of where they live.
NHS England and Public Health England have stated that the trial will begin by the summer of 2017, available to view here:
https://www.gov.uk/government/news/update-on-prep-impact-trial-in-england
The final timescale will be considered at the July meeting of the PrEP Programme Oversight Board (POB) when updated information on the likely timeline of availability of trial drug at trial sites will be provided. Several bids to supply the trial drug were received on the June 29 deadline. If the trial timeline needs to change, new information will be provided in the Stakeholder Update due to be issued after the July 14 PrEP POB.
The Frequently Asked Questions will be published following review at the July meeting of the PrEP POB.
The PrEP Impact trial application was submitted to the Research Ethics Committee (REC) at the end of June. The committee will issue a final ethical opinion within 60 days. The current expectation is that approval will be obtained in time for the drug becoming available. The REC approval timeline is independent of the trial drug procurement process.
Before a trial site can begin to recruit patients, they must provide confirmation of capacity and capability to the Trial co-ordination centre and the timescales for this can vary across localities. This process includes negotiating and finalising local trial contracts and having site staff undergo trial-specific training provided by the Trial co-ordination centre (St Stephen’s Clinical Research). This process will occur in parallel to obtaining national ethics approval and the trial drug procurement activities. Some sites may be in a position to begin trial participant recruitment as soon as the trial drug becomes available.